INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2 H Einsele; S Parekh; D Madduri; B Santomasso; JG Pérez-Larraya; NWV Donk; B Arnulf; M Mateos; KC Braganca; H Varsos; MJ Carrasco-Alfonso; M Akram; N Lendvai; CC Jackson; Y Olyslager; E Zudaire; C Li; D Geng; A Jakubowiak; A Cohen;

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1¿3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY ME Agha; AD Cohen; D Madduri; YC Cohen; M Delforge; J Hillengass; H Goldschmidt; K Weisel; M Raab; C Scheid; JM Schecter; KC Braganca; H Varsos; L Wang; M Vogel; MJ Carrasco-Alfonso; M Akram; X Wu; T Nesheiwat; H Einsele;

LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES LJ Costa; NWCJV Donk; L Rosinol; R Popat; Be semer; J Martinez-Lopez; D Trancucci; T Stephenson; K Chastain; N Bahlis;